XOMA Initiates Phase 2 Proof-of-Concept Study of XOMA 213
28. Juni 2016 09:01 ET
|
XOMA Corporation
BERKELEY, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its Phase...